Summary and Outlook
In recent years, with the rapid development of Shanghai’s biopharmaceutical industry, the demand for office and industrial space by related companies has surged, especially the vacancy rate of core industrial parks has remained low, and high-standard R&D properties are even more difficult to find. At the same time, a group of higher-standard and higher-quality R&D properties that have been newly built or renovated into the market in the past two years have also met and matched the needs of a group of companies that have higher requirements for infrastructure quality.
According to Colliers’ insights from tracking industry development over the years, biomedicine has long-term positive fundamentals, potential new technologies and fields will continue to be favored by the capital market, and innovation is still the core driving force. Therefore, we believe that Shanghai, especially those areas where innovative talents gather and the industrial chain has a certain maturity, will continue to be favored by biopharmaceutical companies for location selection.
In the case of limited new supply in core industrial parks, how to attract more accurate positioning enterprises, how to seize regional characteristics and enterprise trends to build or transform more competitive products, and set up more scientific and efficient operation teams to improve the property Long-term value will also become a topic and opportunity for developers and investors.
Overtaking in the corner, the leap from a pharmaceutical power to a pharmaceutical power
In the post-epidemic era, my country’s economy is still facing greater growth pressure. The Central Economic Work Conference at the end of 2021 put forward the important goal of stabilizing growth, and the two sessions this year also set the GDP growth rate at 5.5%. Under the interaction of factors such as the accelerated aging of the population, the three-child policy and the repeated outbreak of the new crown epidemic in China, the biomedical industry is bucking the trend and has become one of the most significant growth industries in my country in recent years, and it is also ranked in the national “14th Five-Year Plan”. planning is paramount.
my country’s “14th Five-Year Plan” calls for an average annual increase of 7% in pharmaceutical R&D expenditure by 2025, of which at least 8% is dedicated to basic scientific research; policy support and about 100 billion yuan of financial support are provided for the three major biopharmaceuticals At the same time, it is required to set up a group of national laboratories and reorganize state key laboratories to focus on the innovation of biomedicine.
Although from the perspective of the global competition pattern, the innovation of biomedicine is still concentrated in the pharmaceutical powerhouses such as Europe and the United States. However, with the strengthening of national policy support, the cultivation of basic research talents and the continuous accumulation of technology, my country’s biopharmaceutical industry is expected to overtake the curve. Pioneer in biomedical innovation.
To view the full report click here
Note: The articles on this site have not been posted and shared by netizens or institutions unless they are marked as original. If there is any need for publicity or infringement, please contact [email protected].
This article is reprinted from: https://www.dx2025.com/archives/168212.html
This site is for inclusion only, and the copyright belongs to the original author.